Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme.
Vitamin K occurs in the natural world in several forms, including a plant form, phylloquinone (PK), and a bacterial form, menaquinones (MKs). In many species, including humans, PK is a minor constituent of hepatic vitamin K content, with most hepatic vitamin K content comprising long-chain MKs. Menaquinone-4 (MK-4) is ubiquitously present in extrahepatic tissues, with particularly high concentrations in the brain, kidney and pancreas of humans and rats. It has consistently been shown that PK is endogenously converted to MK-4 (refs 4-8). This occurs either directly within certain tissues or by interconversion to menadione (K(3)), followed by prenylation to MK-4 (refs 9-12). No previous study has sought to identify the human enzyme responsible for MK-4 biosynthesis. Previously we provided evidence for the conversion of PK and K(3) into MK-4 in mouse cerebra. However, the molecular mechanisms for these conversion reactions are unclear. Here we identify a human MK-4 biosynthetic enzyme. We screened the human genome database for prenylation enzymes and found UbiA prenyltransferase containing 1 (UBIAD1), a human homologue of Escherichia coli prenyltransferase menA. We found that short interfering RNA against the UBIAD1 gene inhibited the conversion of deuterium-labelled vitamin K derivatives into deuterium-labelled-MK-4 (MK-4-d(7)) in human cells. We confirmed that the UBIAD1 gene encodes an MK-4 biosynthetic enzyme through its expression and conversion of deuterium-labelled vitamin K derivatives into MK-4-d(7) in insect cells infected with UBIAD1 baculovirus. Converted MK-4-d(7) was chemically identified by (2)H-NMR analysis. MK-4 biosynthesis by UBIAD1 was not affected by the vitamin K antagonist warfarin. UBIAD1 was localized in endoplasmic reticulum and ubiquitously expressed in several tissues of mice. Our results show that UBIAD1 is a human MK-4 biosynthetic enzyme; this identification will permit more effective decisions to be made about vitamin K intake and bone health.
Nakagawa
Kimie
K
Department of Hygienic Sciences, Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan.
Hirota
Yoshihisa
Y
Sawada
Natsumi
N
Yuge
Naohito
N
Watanabe
Masato
M
Uchino
Yuri
Y
Okuda
Naoko
N
Shimomura
Yuka
Y
Suhara
Yoshitomo
Y
Okano
Toshio
T
D000818:Animals; D016367:Baculoviridae / Q000235:genetics / Q000502:physiology; D001842:Bone and Bones / Q000378:metabolism; D002460:Cell Line; D004122:Dimethylallyltranstransferase; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D010006:Osteoblasts; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D018411:Spodoptera / Q000166:cytology / Q000821:virology; D014812:Vitamin K / Q000037:antagonists & inhibitors / Q000378:metabolism; D010837:Vitamin K 1 / Q000378:metabolism; D024482:Vitamin K 2 / Q000031:analogs & derivatives* / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D014859:Warfarin / Q000494:pharmacology
D011506:Proteins; D034741:RNA, Small Interfering; D024482:Vitamin K 2; D014812:Vitamin K; C030814:menatetrenone; D014859:Warfarin; D010837:Vitamin K 1; D004122:Dimethylallyltranstransferase; C425464:UBIAD1 protein, human